Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3109/15412555.2014.991864 http://scihub22266oqcxt.onion/10.3109/15412555.2014.991864 C4778540!4778540!25692310     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 298.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 298.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 298.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       COPD 2015 ; 12 (5): 484-93 Nephropedia Template TP {{tp|p=25692310|t=2015. One-Year Safety of Olodaterol Once Daily via RespimatŪ in Patients with GOLD 2?4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis |pdf=|usr=}}{{25692310}} gab.com Text One-Year Safety of Olodaterol Once Daily via RespimatŪ in Patients with GOLD 2 4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis JO: COPD http://www.kidney.de/pget.php?&tw=1&pmid=25692310 #FOAvip The novel long-acting ?2-agonist olodaterol demonstrated an acceptable safety profile in short-term phase II clinical studies. This analysis of four randomized, double-blind, placebo-controlled, parallel-group, phase III studies (1222.11, NCT00782210; 1222.12, NCT00782509; 1222.13, NCT00793624; 1222.14, NCT00796653) evaluated the long-term safety of olodaterol once daily (QD) in a large cohort of patients with moderate to very severe (Global initiative for chronic Obstructive Lung Disease 2?4) chronic obstructive pulmonary disease (COPD). The studies compared olodaterol (5 or 10 ?g) QD via RespimatŪ, formoterol 12 ?g twice daily (BID) via AerolizerŪ (1222.13 and 1222.14), and placebo for 48 weeks. Patients continued receiving background maintenance therapy, with ?60% receiving concomitant cardiovascular therapy and 25% having a history of concomitant cardiac disease. Pre-specified analyses of pooled data assessed the adverse events (AEs) and serious AEs in the whole population, and in subgroups with cardiac disease, along with in-depth electrocardiogram and Holter monitoring. In total, 3104 patients were included in the safety analysis: 876 received olodaterol 5 ?g, 883 received olodaterol 10 ?g, 885 received placebos, and 460 received formoterol 12 ?g BID. Overall incidence of on-treatment AEs (71.2%), serious AEs (16.1%), and deaths (1.7%) were balanced across treatment groups. Respiratory and cardiovascular AEs, including major adverse cardiac events, were reported at similar frequencies in placebo and active treatment groups. The safety profiles of both olodaterol 5 ?g (marketed and registered dose) and 10 ?g QD delivered via RespimatŪ are comparable to placebo and formoterol BID in this population, with no safety signals identified. Twit Text FOAVip One-Year Safety of Olodaterol Once Daily via RespimatŪ in Patients with GOLD 2 4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis ????COPD http://www.kidney.de/pget.php?&tw=1&pmid=25692310 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25692310 #FOAvip English Wikipedia <ref>{{Cite pmid|25692310}}</ref> One-Year Safety of Olodaterol Once Daily via RespimatŪ in Patients with GOLD 2?4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis #MMPMID25692310 McGarvey L; Niewoehner D; Magder S; Sachs P; Tetzlaff K; Hamilton A; Korducki L; Bothner U; Vogelmeier C; Koch A; Ferguson GT COPD 2015[Sep]; 12 (5): 484-93 PMID25692310show ga The novel long-acting ?2-agonist olodaterol demonstrated an acceptable safety profile in short-term phase II clinical studies. This analysis of four randomized, double-blind, placebo-controlled, parallel-group, phase III studies (1222.11, NCT00782210; 1222.12, NCT00782509; 1222.13, NCT00793624; 1222.14, NCT00796653) evaluated the long-term safety of olodaterol once daily (QD) in a large cohort of patients with moderate to very severe (Global initiative for chronic Obstructive Lung Disease 2?4) chronic obstructive pulmonary disease (COPD). The studies compared olodaterol (5 or 10 ?g) QD via RespimatŪ, formoterol 12 ?g twice daily (BID) via AerolizerŪ (1222.13 and 1222.14), and placebo for 48 weeks. Patients continued receiving background maintenance therapy, with ?60% receiving concomitant cardiovascular therapy and 25% having a history of concomitant cardiac disease. Pre-specified analyses of pooled data assessed the adverse events (AEs) and serious AEs in the whole population, and in subgroups with cardiac disease, along with in-depth electrocardiogram and Holter monitoring. In total, 3104 patients were included in the safety analysis: 876 received olodaterol 5 ?g, 883 received olodaterol 10 ?g, 885 received placebos, and 460 received formoterol 12 ?g BID. Overall incidence of on-treatment AEs (71.2%), serious AEs (16.1%), and deaths (1.7%) were balanced across treatment groups. Respiratory and cardiovascular AEs, including major adverse cardiac events, were reported at similar frequencies in placebo and active treatment groups. The safety profiles of both olodaterol 5 ?g (marketed and registered dose) and 10 ?g QD delivered via RespimatŪ are comparable to placebo and formoterol BID in this population, with no safety signals identified. äOne-Year Safety of Olodaterol Once Daily via RespimatŪ in Patients wit(epmc).pdf DeepDyve Pubget Overpricing